XBiotech Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
87
- Stock Symbol
-
XBIT
- Share Price
-
$1.96
- (As of Friday Closing)
XBiotech General Information
Description
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Contact Information
Website
www.xbiotech.comCorporate Office
- 5217 Winnebago Lane
- Austin, TX 78744
- United States
Corporate Office
- 5217 Winnebago Lane
- Austin, TX 78744
- United States
XBiotech Stock Performance
As of 13-Nov-2026, XBiotech’s stock price is $1.96. Its current market cap is $59.8M with 30.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.96 | $1.96 | $1.80 - $2.73 | $59.8M | 30.5M | 59.9K | -$1.48 |
XBiotech Financials Summary
As of 30-Jun-2026, XBiotech has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (45,337) | (74,501) | (52,708) | (80,443) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (47,866) | (49,210) | (45,823) | (32,990) |
| Net Income | (45,133) | (45,540) | (38,531) | (24,557) |
| Total Assets | 133,651 | 150,082 | 199,093 | 226,615 |
| Total Debt | 0 | 0 | 10,250 | 0 |
XBiotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
XBiotech Comparisons
Industry
Financing
Details
XBiotech Competitors (107)
One of XBiotech’s 107 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| Azitra | Formerly VC-backed | Branford, CT | ||||
| Light Chain Bioscience | Formerly PE-Backed | Geneva, Switzerland | ||||
| American Gene Technologies | Venture Capital-Backed | Rockville, MD |
XBiotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
XBiotech Patents
XBiotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024224524-A1 | Herpes zoster treatment | Pending | 23-Feb-2023 | ||
| EP-4669351-A1 | Herpes zoster treatment | Pending | 23-Feb-2023 | ||
| US-20260125453-A1 | Herpes zoster treatment | Pending | 23-Feb-2023 | ||
| WO-2024174020-A1 | Herpes zoster treatment | Inactive | 23-Feb-2023 | ||
| JP-2026508140-A | Treatment for shingles | Pending | 23-Feb-2023 | C07K16/088 |
XBiotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
XBiotech ESG
Risk Overview
Risk Rating
Updated August, 31, 2025
35.35 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
XBiotech FAQs
-
When was XBiotech founded?
XBiotech was founded in 2005.
-
Where is XBiotech headquartered?
XBiotech is headquartered in Austin, TX.
-
What is the size of XBiotech?
XBiotech has 87 total employees.
-
What industry is XBiotech in?
XBiotech’s primary industry is Biotechnology.
-
Is XBiotech a private or public company?
XBiotech is a Public company.
-
What is XBiotech’s stock symbol?
The ticker symbol for XBiotech is XBIT.
-
What is the current stock price of XBiotech?
As of 13-Nov-2026 the stock price of XBiotech is $1.96.
-
What is the current market cap of XBiotech?
The current market capitalization of XBiotech is $59.8M.
-
Who are XBiotech’s competitors?
Inovio Pharmaceuticals, Aclaris Therapeutics, Azitra, Light Chain Bioscience, and American Gene Technologies are some of the 107 competitors of XBiotech.
-
What is XBiotech’s annual earnings per share (EPS)?
XBiotech’s EPS for 12 months was -$1.48.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
